Global Urokinase Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Urokinase Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease present in humans and other animals. The human urokinase protein was discovered, but not named, by McFarlane and Pilling in 1947. Urokinase was originally isolated from human urine, and it is also present in the blood and in the extracellular matrix of many tissues. The primary physiological substrate of this enzyme is plasminogen, which is an inactive form (zymogen) of the serine protease plasmin.

Market Overview:

The latest research study on the global Urokinase market finds that the global Urokinase market reached a value of USD 464.23 million in 2022. It’s expected that the market will achieve USD 590.0 million by 2028, exhibiting a CAGR of 4.08% during the forecast period.

Limitations

Human urine is the onlySource of urokinase production. The amount of urokinase in urine is very low. Only one ton of urokinase can be extracted in one ton of urine. With the development of urbanization, the reduction of public toilets, urine collection becomes more and more difficult, which leads to an increase in the price of raw materials, thereby affecting the supply of urokinase.
The half-life of urokinase products in the body is less than 20 minutes, and there is a tendency for systemic bleeding to be administered in large
quantities over a long period of time. Moreover, the targeting of the drug is poor, and other bleeding points are easily caused during the treatment.
Because the raw materials of urokinase are relatively easy to obtain, there are some companies on the market that process urokinase in the absence of health standards. This will seriously disrupt the urokinase market.

Region Overview:

From 2023-2028, China is estimated to witness robust growth prospects.

Company Overview:

Nanjing Nanda Pharmaceutical is one of the major players operating in the Urokinase market, holding a share of 28.60% in 2019.

Microbix Biosystems Inc. (TSX:MBX) (Microbix or the Company) a developer and marketer of biological products and technologies, announces that it has consulted with the U.S. Food and Drug Administration (the FDA) regarding the Company's plans to return its thrombolytic biologic drug, Kinlytic® Urokinase (Kinlytic), to the U.S. market.

Microbix believes the results of its consultation will accelerate its work to obtain financing, complete its relaunch program and then submit an application to FDA for re-approval in the U.S. market. The Company has already received expressions of interest to license or acquire Kinlytic and to provide full funding for its re-launch program. Following its consultation with FDA, the Company now intends to accelerate its work to conclude such an agreement. Microbix has also established that Kinlytic may be produced via contract manufacturing, a factor that should shorten the timeline of its return to market. The Company plans to retain a significant interest in the economics of Kinlytic following an agreement to enable its re-launch program.

Segmentation Overview:

Among different product types, Freeze-dried powder segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Hospital use segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Urokinase market covered in Chapter 3:

Jiangxi Haoran Bio-Pharma
Nanjing Nanda Pharmaceutical
Wanhua Biochem
Taj Pharmaceuticals
Microbix Biosystems Inc
Jiangsu Aidea Pharmaceutica
Zydus Cadila
Livzon Pharmaceutical Group

In Chapter 4 and Chapter 14.2, on the basis of types, the Urokinase market from 2018 to 2029 is primarily split into:

Injection
Freeze-dried powder

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Urokinase market from 2018 to 2029 covers:

Hospital use
Clinic
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)